Y-mAbs Therapeutics, Inc. (YMAB)

Market Cap	217.50M
Revenue (ttm)	87.69M
Net Income (ttm)	-29.67M
Shares Out	45.22M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,016
Open	4.950
Previous Close	4.960
Day's Range	4.730 - 4.940
52-Week Range	4.250 - 17.780
Beta	0.65
Analysts	Buy
Price Target	18.73 (+289.4%)
Earnings Date	Mar 4, 2025

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of pati...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 21, 2018
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: YMAB
• Website: https://www.ymabs.com

Financial Performance

In 2024, Y-mAbs Therapeutics's revenue was $87.69 million, an increase of 3.38% compared to the previous year's $84.82 million. Losses were -$29.67 million, 38.5% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $18.73, which is an increase of 289.40% from the latest price.

Price Target

$18.73

(289.40% upside)

Analyst Consensus: Buy